Stephanie Tung | Medical Services
Programs & Services
Languages
- English
Stephanie Tung | Education
Undergraduate School
University of Toronto
2010, Toronto, Ontario, Canada
Graduate School
University of Toronto
2013, Toronto, Ontario, Canada
Medical School
Royal College of Surgeons in Ireland
2017, Dublin, Ireland
Internship
Pediatrics
Johns Hopkins Pediatric Residency Program
2018, Baltimore, MD
Residency
Pediatrics
Johns Hopkins Pediatric Residency Program
2020, Baltimore, MD
Fellowship
Neonatal-Perinatal Medicine
Harvard Neonatal Perinatal Medicine Fellowship
2023, Boston, MA
Stephanie Tung | Certifications
- American Board of Pediatrics (General)
Stephanie Tung | Professional History
Dr. Stephanie Tung is an Attending Physician in Medicine in the Division of Newborn Medicine at Boston Children’s Hospital. She is also an Instructor of Pediatrics at Harvard Medical School. Dr. Tung is a graduate of the University of Toronto and received her medical degree from the Royal College of Surgeons in Ireland. She completed her training in pediatrics at the Johns Hopkins Pediatric Residency Program in Baltimore and her neonatology training in the Harvard Neonatal-Perinatal Medicine Fellowship program.
Dr. Tung's research focuses on evaluating the long-term immunologic implications of bronchopulmonary dysplasia.
Stephanie Tung | Publications
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer. Oncologist. 2024 Dec 19. View Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer. Abstract
Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases. Semin Perinatol. 2023 04; 47(3):151730. View Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases. Abstract
Fetal Disseminated Malignant Rhabdoid Tumor. Neoreviews. 2022 08 01; 23(8):e595-e602. View Fetal Disseminated Malignant Rhabdoid Tumor. Abstract
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget. 2016 Nov 08; 7(45):72608-72621. View Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Abstract
PPARa and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013 Aug 08; 122(6):969-80. View PPARa and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Abstract
PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 2013 Apr; 27(5):1090-9. View PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Abstract
A role for Danazol in chronic lymphocytic leukemia. Leukemia. 2012 Jul; 26(7):1684-6. View A role for Danazol in chronic lymphocytic leukemia. Abstract